Effect of dimethyl fumarate on gray and white matter pathology in subjects with relapsing multiple sclerosis: a longitudinal study

Background and purpose Dimethyl fumarate (DMF) is an oral treatment for relapsing‐remitting multiple sclerosis (MS) with anti‐inflammatory and possible neuroprotective properties. Its effect on white matter and gray matter pathology is still not fully understood. The aim of the study was to characte...

Full description

Saved in:
Bibliographic Details
Published in:European journal of neurology 2018-03, Vol.25 (3), p.584-e36
Main Authors: Zivadinov, R., Hagemeier, J., Bergsland, N., Tavazzi, E., Weinstock‐Guttman, B.
Format: Article
Language:English
Subjects:
Adult
Anisotropy
Correlation analysis
Diffusion
Diffusion Tensor Imaging
Diffusivity
Dimethyl Fumarate - pharmacology
Female
healthy individuals
Humans
Immunosuppressive Agents - pharmacology
Inflammation
Longitudinal Studies
Magnetic resonance imaging
Male
Middle Aged
Multiple sclerosis
Multiple Sclerosis, Relapsing-Remitting - diagnostic imaging
Multiple Sclerosis, Relapsing-Remitting - drug therapy
Multiple Sclerosis, Relapsing-Remitting - pathology
Neuroprotection
Neuroprotective Agents - pharmacology
normal‐appearing white matter
Pathology
Patients
Single-Blind Method
Spatial analysis
Substantia alba
Substantia grisea
Thalamus
Thalamus - diagnostic imaging
Thalamus - pathology
tract‐based spatial statistics
White Matter - diagnostic imaging
White Matter - pathology
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and purpose Dimethyl fumarate (DMF) is an oral treatment for relapsing‐remitting multiple sclerosis (MS) with anti‐inflammatory and possible neuroprotective properties. Its effect on white matter and gray matter pathology is still not fully understood. The aim of the study was to characterize the effect of DMF on normal‐appearing white matter (NAWM) and thalamic pathology longitudinally. Methods In this observational, longitudinal, 24‐month magnetic resonance imaging study, 75 patients with relapsing‐remitting MS treated with DMF and 40 age‐ and sex‐matched healthy individuals were enrolled. Regional diffusion tensor imaging metrics and tract‐based spatial statistics analyses were used to assess differences between groups. Mean diffusivity, axial diffusivity, radial diffusivity and fractional anisotropy were measured in the thalamus and NAWM. Baseline differences and changes over time were evaluated within and between study groups. Results At baseline, patients with MS showed significantly increased diffusivity and decreased fractional anisotropy in the thalamus (P 
ISSN:1351-5101
1468-1331
DOI:10.1111/ene.13562